8 results about "Fecal microbiota" patented technology

The application discloses a kind of based on 5 kinds of bacteria combination's flora transplantation donor screening technique and its application in tumor immunotherapy, the intestinal flora includes Eubacterium rectale, Adlercreutzia equolifaciens, Megamonas hypermegale, Lachnospiraceae bacterium (5_1_63FAA), Gordonibacter pamelaeae One or more of them.The application is screened and found that the abundance of the intestinal flora in the obese cancer patients with immune checkpoint inhibitor treatment response is significantly improved, and can be used to predict the immune checkpoint inhibitor treatment effect of cancer patients.The flora transplantation preparation containing the relative abundance of the intestinal flora is greater than or equal to 8.51%, and after combination treatment with immune checkpoint inhibitor, the tumor immunotherapy effect can be significantly improved.

This invention relates to fecal microbiota transplantation (FMT) formulations for treating lung cancer, their screening methods, and applications. The invention establishes a microbiome-based quantitative screening system based on the characteristics of the lung cancer immune microenvironment, achieving a precise match between donor screening criteria and tumor-specific immune regulation needs. This overcomes the limitations of traditional FMT formulation preparations that rely on universal health standards, providing reliable support for clinical applications. Furthermore, the invention develops a combined application strategy of FMT formulations and immune checkpoint inhibitors, which can significantly improve disease control rates and prolong progression-free survival in lung cancer patients, providing an innovative solution to overcome drug resistance challenges in lung cancer immunotherapy.

The present application relates to a quality control product for quality evaluation of a preparation for intestinal flora transplantation, a preparation method and application thereof. The quality control product comprises a complex microbial component, an internal standard component, a simulated matrix and a stabilizer. The present application adopts a "multi-donor mixing" method, and compared with a scheme based on cultured strains, the quality control product prepared by the present application is highly consistent with a real FMT preparation in terms of species composition, relative proportion and bacterial activity state, and the quality control result has a strong clinical relevance. By constructing a "core bacterial spectrum", the complex flora quality control becomes simple, focused and cost controllable. In addition, the use of bifidobacterium as an internal standard has better compatibility with the sample matrix, more accurate monitoring and completely eliminates the risk of exogenous contamination.

Disclosures herein relate to methods of producing oral powdered compositions for fecal microbiota transplant including desired microbes and related methods of treatment. Procedures for producing the powdered composition may include filtering a fecal sample, separating particulate matter of the filtrate, repeatedly resuspending the sediment and separating particulate matter, diluting the supernatant and repeatedly separating particulate matter out of the supernatant, resuspending the sediment in a cryoprotectant to obtain a mixture, and freeze-drying the mixture to obtain a freeze-dried, powdered composition, wherein the powdered composition may be substantially tasteless, odorless, and colorless. The FMT composition has an odor as evaluated with a confidence of 95% to be odorless for more than 50% of the population using a triangular test and a flavor as evaluated with a confidence of 80% to be flavorless for more than 50% of the population using the triangular test.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition.The invention also provides processes for its preparation as well as it use in therapy.The live-cell based composition of the invention is stable at mild conditions.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of live microorganisms and one or more pharmaceutically acceptable water-absorbing excipients, wherein the water content of the composition is between 0.5% and 30% by weight of the total composition, as determined according to the European Pharmacopoeia 9.4 section 2.5.12. The present invention also provides a process for its preparation and its use in therapy. The live cell-based composition of the present invention is stable under mild conditions.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of live microorganisms and one or more pharmaceutically acceptable water-absorbing excipients, wherein the water content of the composition is between 0.5% and 30% by weight of the total composition, as determined according to the European Pharmacopoeia 9.4 section 2.5.12. The present invention also provides a process for its preparation and its use in therapy. The live cell-based composition of the present invention is stable under mild conditions.